BioSight
Companies
AGIOS PHARMACEUTICALS, INC. logo

AGIO

NASDAQCAMBRIDGE, MA
AGIOS PHARMACEUTICALS, INC.

Agios Pharmaceuticals develops and commercializes small-molecule medicines targeting pyruvate kinase (PK) enzymes, with its lead approved product PYRUKYND (mitapivat) used to treat anemia in patients with thalassemia. The company is also pursuing earlier-stage programs in other rare genetic diseases, including a PAH stabilizer candidate (AG-181) for phenylketonuria and an siRNA therapeutic (AG-236) targeting TMPRSS6. Agios has moved beyond the discovery phase and into commercialization and clinical development of multiple product candidates across different therapeutic areas.

Price history not yet available for AGIO.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar